Neuromuscular complications of immune checkpoint inhibitor therapy

作者：Kolb Noah A^*; Trevino Christopher R; Waheed Waqar; Sobhani Fatemeh; Landry Kara K; Thomas Alissa A; Hehir Mike

来源：Muscle & Nerve, 2018, 58(1): 10-22.

DOI：10.1002/mus.26070

• autoimmune drug reaction
• cancer treatment
• immune adverse events
• immune checkpoint inhibitor
• immunotherapy
• neuromuscular

Immune checkpoint inhibitor (ICPI) therapy unleashes the body's natural immune system to fight cancer. ICPIs improve overall cancer survival, however, the unbridling of the immune system may induce a variety of immune-related adverse events. Neuromuscular immune complications are rare but they can be severe. Myasthenia gravis and inflammatory neuropathy are the most common neuromuscular adverse events but a variety of others including inflammatory myopathy are reported. The pathophysiologic mechanism of these autoimmune disorders may differ from that of non-ICPI-related immune diseases. Accordingly, while the optimal treatment for ICPI-related neuromuscular disorders generally follows a traditional paradigm, there are important novel considerations in selecting appropriate immunosuppressive therapy. This review presents 2 new cases, a summary of neuromuscular ICPI complications, and an approach to the diagnosis and treatment of these disorders. Muscle Nerve58: 10-22, 2018

• 出版日期2018-7